We developed 2 unique serially transplantable patient-derived xenograft (PDX) models of STAG2- and RAD21-mutant AML (Figure 4E and Supplemental Figure 4, C and E) and evaluated the efficacy of talazoparib in both models in vivo. This evidence concerns the gene RAD21 and acute myeloid leukemia.